Can "Foolish Courage" Lead to Value Creation?

Developing technology for making enzymes in India at a time when the biotechnology industry barely existed even on a global level - this may be termed as "Foolish Courage,” but the conviction of Kiran Mazumdar-Shaw has yielded Biocon today a market cap of Rs. 29,394 crore.
 
 
 
 
 
  0 Comments
 
 
Login / to join the conversation1